{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TR-701+FA",
    "query": {
      "intervention": "TR-701 FA"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TR-701+FA&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T19:10:24.223Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01461460",
      "title": "A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "TR-701 FA 1200 mg",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400 mg",
          "type": "DRUG"
        },
        {
          "name": "TR-701 FA 200 mg plus Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2011-11-28",
      "completion_date": "2011-12-23",
      "has_results": false,
      "last_update_posted_date": "2018-12-05",
      "last_synced_at": "2026-09-02T19:10:24.223Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01461460"
    },
    {
      "nct_id": "NCT01431833",
      "title": "A PK and Safety Study in Subjects With Hepatic Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "TR-701 FA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 32,
      "start_date": "2011-08",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2016-05-20",
      "last_synced_at": "2026-09-02T19:10:24.223Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431833"
    },
    {
      "nct_id": "NCT06733688",
      "title": "A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tedizolid Phosphate Oral Formulation 1 (Reference)",
          "type": "DRUG"
        },
        {
          "name": "Tedizolid Phosphate Oral Formulation 2 (Test)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "19 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": "2022-03-23",
      "completion_date": "2022-04-15",
      "has_results": false,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-09-02T19:10:24.223Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06733688"
    },
    {
      "nct_id": "NCT01539473",
      "title": "A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TR-701 FA with Tyramine",
          "type": "DRUG"
        },
        {
          "name": "Placebo-controlled withTyramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-02",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2016-05-03",
      "last_synced_at": "2026-09-02T19:10:24.223Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01539473"
    },
    {
      "nct_id": "NCT03176134",
      "title": "A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Bacterial Skin and Skin Structure Infections"
      ],
      "interventions": [
        {
          "name": "Tedizolid phosphate",
          "type": "DRUG"
        },
        {
          "name": "Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "1 Day to 11 Years"
      },
      "enrollment_count": 100,
      "start_date": "2019-01-20",
      "completion_date": "2023-07-06",
      "has_results": true,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-09-02T19:10:24.223Z",
      "location_count": 8,
      "location_summary": "San Diego, California • Chicago, Illinois • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03176134"
    },
    {
      "nct_id": "NCT01271998",
      "title": "Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infection"
      ],
      "interventions": [
        {
          "name": "TR-701 FA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-12-08",
      "completion_date": "2011-01-03",
      "has_results": false,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-09-02T19:10:24.223Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01271998"
    },
    {
      "nct_id": "NCT00983255",
      "title": "Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "TR-701 FA for injection, 200 mg/vial",
          "type": "DRUG"
        },
        {
          "name": "TR-701 FA tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 90,
      "start_date": "2009-09",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2016-05-19",
      "last_synced_at": "2026-09-02T19:10:24.223Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983255"
    },
    {
      "nct_id": "NCT01577459",
      "title": "A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "TR-701 FA with PSE",
          "type": "DRUG"
        },
        {
          "name": "TR-701 FA Placebo with PSE",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 18,
      "start_date": "2012-04-23",
      "completion_date": "2012-06-15",
      "has_results": false,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-09-02T19:10:24.223Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01577459"
    },
    {
      "nct_id": "NCT01421511",
      "title": "TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Skin and Subcutaneous Tissue Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "TR-701 FA",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 666,
      "start_date": "2011-09-15",
      "completion_date": "2013-01-10",
      "has_results": true,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-09-02T19:10:24.223Z",
      "location_count": 35,
      "location_summary": "Dothan, Alabama • Chula Vista, California • Escondido, California + 31 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01421511"
    },
    {
      "nct_id": "NCT01452828",
      "title": "A Pharmacokinetics and Safety Study in Subjects With Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "TR-701 FA single infusion",
          "type": "DRUG"
        },
        {
          "name": "TR-701 FA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-10",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2016-05-03",
      "last_synced_at": "2026-09-02T19:10:24.223Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01452828"
    }
  ]
}